TickerTalks
Browse all tickers →
TickerTalks›$NTHI
NTNTHI

Neonc Technologies Holdings, Inc.

$NTHI·$86M·Biotechnology·Healthcare
$3.31+0.3%YTD-60.9%1Y-68.1%
Price updated 2d ago·X counts updated 6h ago
NTNTHI
$NTHINeonc Technologies Holdings, Inc.
$3.31+0.30%36 posts1.2×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $NTHI on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

36X posts · last 7 days
Sep 10Sep 27
Chatter Meter
1.2×
QuietNormal · 1×Loud

How loud $NTHI's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 82% of tracked names.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $NTHI — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-09-28

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

NeOnc just redeemed all Series A preferred (-major dilution risk) and CEO Heshmatpour bought $115K at $3.30 — Roth sees a 2026 trial catalyst on the intranasal brain-cancer platform.

NeOnc Technologies Holdings is a clinical-stage biopharma developing NEO100, an intranasal drug-delivery platform for CNS diseases — a broken-story micro-cap that just executed two specific de-risking events. The stock is down 61% YTD at 4% of the 52-week range.

  • The Sept 21 Series A Preferred redemption is the key balance-sheet event: all outstanding preferred redeemed at $965/share for ~$5.79M and Certificate of Elimination filed — permanent removal of the liquidation-preference overhang that was suppressing common valuation.
  • CEO Amir Heshmatpour bought 35,000 shares on Sept 15 for ~$115K at $3.30 — real open-market executive buying at these lows, which reads with the Roth coverage initiation (Sept 24) that flags a potential 2026 trial catalyst.
  • The Sept 10 registered direct offering ($14.9M gross at $4.20 combined) partially offsets the preferred cleanup — capital raised, though dilutive at these levels; runway extended for the intranasal-delivery clinical program.

Q3 earnings on Nov 12 is the confirmation — a firm NEO100 Phase 2a data update or a pivotal-trial timeline restarts the story; another quarter of program commentary without a data print and the tiny-float tape stays speculative.

What to watch: Q3 earnings on Nov 12 plus a NEO100 Phase 2a data update — a firm pivotal-trial timeline restarts the story; another quarter of program commentary without a data print and the tape stays speculative.

On the calendar: 2026-11-12 — Q3 earnings

no sentimentseries a redemptionceo open market buy

Read the AI verdict on $NTHI

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing targeted molecular delivery therapies for central nervous system cancers and diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NTHI.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $NTHI

Neutral — Clinical-stage biotech developing targeted molecular delivery therapies for central nervous system cancers and diseases.

Top industry ETF

$IBBiShares Biotechnology ETF
+23.6%YTD
+50.8%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
259%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-19.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
284%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 10, 2026$-0.58$-0.12-397.1%
Q1 2026May 18, 2026$-0.38$-0.22-73.5%
Q4 2025Mar 31, 2026$-0.40$-0.37-7.3%
Q3 2025Nov 14, 2025$-0.45$-0.37-21.6%
Next earningsThu, Nov 12·consensus EPS $-0.25

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0-100.0%——$-0.38$-7.0M
Q4 FY25$0———$-0.81$-3.6M
Q3 FY25$0———$-0.45$-5.8M
Q2 FY25$0———$-0.30$-5.3M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$40K$40K – $40K-$1.39-$1.77 – -$0.745
FY27$40K$40K – $40K-$1.11-$1.76 – -$0.505
FY28$40K$40K – $40K-$1.09-$1.30 – -$0.893
FY29$42.1M$42.1M – $42.1M-$0.46-$0.46 – -$0.461
FY30$117.3M$117.3M – $117.3M$0.68$0.68 – $0.682

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.4%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-15.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-46.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 5.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.505-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KCharter amendmentSep 218-K — Item 3.03 · Item 5.03: Charter amendment · Item 7.01: Press release / Reg FD
AI summary

NeoNc Technologies Holdings (NTHI) redeemed all outstanding Series A Preferred Stock at $965 per share for a cumulative redemption of approximately $5.79 million, then filed a Certificate of Elimination with Delaware on September 18, 2026 to permanently terminate the Series A Preferred designation (no shares remain outstanding). The Board approved the elimination. This clean-up of preferred equity simplifies the capital structure by removing the Series A liquidation preference and any associated dividend obligations, an accretive balance sheet housekeeping action.

8-KPress release / Reg FDSep 178-K — Item 7.01: Press release / Reg FD
AI summary

NeOnc Technologies Holdings, Inc. (NTHI) disclosed via Reg FD that CEO, President, and Executive Chairman Amir Heshmatpour purchased 35,000 shares of NTHI common stock in the open market on September 15, 2026, for approximately $115,400 at a weighted average price of approximately $3.30 per share. An open-market insider purchase by the company's top executive is a noteworthy confidence signal at a small biopharma trading near single digits.

8-KMaterial agreementSep 108-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

NeOnc Technologies Holdings entered securities purchase agreements for a registered direct offering of 2,610,715 shares and 960,715 pre-funded warrants, plus 3,571,430 common warrants, at a combined price of $4.20 per share with accompanying warrants, raising approximately $14.9 million gross. Pre-funded warrants prevent investors from exceeding 4.99%/9.99% ownership thresholds. Proceeds will fund NeOnc's working capital and clinical activities for its neuro-oncology platform.

424B5Prospectus supplement (offering)Sep 10424B5
AI summary

NeOnc Technologies filed a 424B5 prospectus supplement for the registered direct offering of shares, pre-funded warrants, and common warrants to institutional investors, corresponding to the securities purchase agreements disclosed in the concurrent 8-K. Pre-funded warrants are exercisable at $0.0001 per share and the common warrants have a separate exercise price. This provides the formal registered offering disclosures under NeOnc's shelf registration.

8-K/AOfficer or director change (amended)Aug 218-K/A — Item 5.02: Officer or director change
AI summary

NeonC Technologies Holdings, Inc. (NTHI, Calabasas CA), a medical device company, filed an amended 8-K/A on August 18-21, 2026, amending a June 27, 2026 current report covering changes in executive officers or directors (Item 5.02). This amendment corrects or supplements the original leadership change disclosure from June. Administrative amendment to a prior leadership change filing.

8-KShareholder voteAug 208-K — Item 5.07: Shareholder vote
8-KPress release / Reg FDAug 138-K — Item 7.01: Press release / Reg FD
AI summary

NeOnc Technologies Holdings, Inc. (NTHI), a Calabasas, California-based clinical-stage biotech listed on Nasdaq, filed an 8-K on August 13, 2026 disclosing that it hosted an investor conference call on August 12, 2026 to discuss results from the Phase 2a portion of its clinical study NEO100-01. The full transcript of the call was furnished as Exhibit 99.1 under Regulation FD to ensure broad investor access to the clinical data simultaneously. NEO100 is NeOnc's lead product candidate, and Phase 2a data represents a meaningful de-risking milestone for the pipeline. Investors in clinical-stage oncology names should review the transcript directly for efficacy rates, safety signals, and management's commentary on the path to a pivotal trial.

8-KPress release / Reg FDAug 128-K — Item 7.01: Press release / Reg FD
AI summary

NeOnc Technologies (NTHI) filed an 8-K on August 13, 2026 (event date August 12) under Item 7.01 (Regulation FD), furnishing a public investor communication concurrently with its Q2 2026 earnings disclosure. The excerpt is the cover page; the actual investor materials are in the attached exhibit. NeOnc Technologies is a clinical-stage oncology company developing intranasal drug delivery therapies for brain cancer. This Reg FD filing is typically an investor presentation or conference slide deck.

+ 34 other (11 8-Ks · 3 EFFECTs · 3 424B5s · 3 S-3s) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalystglobenewswire.com·4d agoNeOnc's Delivery may Finally Change the Equation for Brain Cancer's Next Frontierglobenewswire.com·6d agoNeOnc Charting New Nasal Route to Treating Brain Cancerglobenewswire.com·7d agoNeOnc Eliminates Major Dilution Risk as Clinical Story Acceleratesglobenewswire.com·11d agoNeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilutionglobenewswire.com·11d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$VKTX$MRNA$RARE$NWBO$AURA$ARCT$IBRX$NKTR
Voices on X · last 7 days

No standout posts about $NTHI on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport